Scarica l'app Stockscreener
7.45
4.73%
-0.37
Precedente Chiudi:
$7.82
Aprire:
$7.71
Volume 24 ore:
2.21M
Relative Volume:
1.73
Capitalizzazione di mercato:
$509.41M
Reddito:
-
Utile/perdita netta:
$-297.11M
Rapporto P/E:
-1.7009
EPS:
-4.38
Flusso di cassa netto:
$-216.95M
1 W Prestazione:
-5.58%
1M Prestazione:
-14.66%
6M Prestazione:
-36.92%
1 anno Prestazione:
-9.26%
Intervallo 1D:
$7.39
$7.8299
Intervallo di 1 settimana:
$7.39
$8.60
Portata 52W:
$6.065
$19.71
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Nome
Phathom Pharmaceuticals Inc
Settore
Industria
Telefono
(877) 742-8466
Indirizzo
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Confronta PHAT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
7.45 | 509.41M | 0 | -297.11M | -216.95M | -5.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-03 | Iniziato | Stifel | Buy |
| 2024-01-05 | Reiterato | Needham | Buy |
| 2023-08-09 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Iniziato | Craig Hallum | Buy |
| 2022-10-21 | Iniziato | Jefferies | Buy |
| 2022-05-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2021-02-17 | Iniziato | BMO Capital Markets | Outperform |
| 2021-02-02 | Iniziato | Guggenheim | Buy |
| 2020-06-26 | Downgrade | Goldman | Neutral → Sell |
| 2019-11-20 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Goldman | Neutral |
| 2019-11-19 | Iniziato | Jefferies | Buy |
| 2019-11-19 | Iniziato | Needham | Buy |
Mostra tutto
Phathom Pharmaceuticals Inc Borsa (PHAT) Ultime notizie
Phathom Pharmaceuticals CFO Molly Henderson sells $10,328 in stock - Investing.com India
Insider Selling: Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) CFO Sells 1,291 Shares of Stock - MarketBeat
Phathom Pharmaceuticals COO sells shares for $8,944 - Investing.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 2%What's Next? - MarketBeat
Phathom Pharmaceuticals Inc (PHAT) Recovers 28.94% From Low: Are We There Yet? - Stocks Register
FDA Tracker: FDA Hands Out Atopic Dermatitis Approvals to Galderma, Organon - BioSpace
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up After Insider Buying Activity - Defense World
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Frank Karbe buys $99,083 in Phathom Pharmaceuticals stock By Investing.com - Investing.com Australia
Frank Karbe buys $99,083 in Phathom Pharmaceuticals stock - Investing.com India
Phathom Pharmaceuticals director Asit Parikh buys $81,248 in stock By Investing.com - Investing.com South Africa
How To Trade (PHAT) - Stock Traders Daily
Insider Buying: Asit Parikh Acquires 10,000 Shares of Phathom Ph - GuruFocus.com
Frank Karbe Increases Stake in Phathom Pharmaceuticals Inc (PHAT) - GuruFocus.com
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up on Insider Buying Activity - MarketBeat
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Director Acquires $99,125.00 in Stock - MarketBeat
Phathom Pharmaceuticals director Asit Parikh buys $81,248 in stock - Investing.com
Insider Sellers Might Regret Selling Phathom Pharmaceuticals Shares at a Lower Price Than Current Market Value - Simply Wall St
Charles Schwab Investment Management Inc. Purchases 6,990 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World
Phathom Pharmaceuticals Submits Citizen Petition to FDA for Correction of Orange Book Listings for VOQUEZNA Tablets - Defense World
Phathom Pharma shares stay Buy rated on extended vonoprazan exclusivity to 2032 - Investing.com Canada
Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)? - MSN
Phathom Pharmaceuticals (NASDAQ:PHAT) Receives "Buy" Rating from HC Wainwright - MarketBeat
Phathom Pharmaceuticals: The Large Drop Is, Well, Unfathomable (NASDAQ:PHAT) - Seeking Alpha
Phathom Pharmaceuticals seeks FDA clarity on drug exclusivity - Investing.com
Phathom Pharmaceuticals seeks FDA clarity on drug exclusivity By Investing.com - Investing.com UK
Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets - The Manila Times
Phathom Pharmaceuticals Submits Citizen Petition to FDA - GlobeNewswire
Fmr LLC Boosts Stock Holdings in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Down -54.05% in 4 Weeks, Here's Why Phathom Pharmaceuticals (PHAT) Looks Ripe for a Turnaround - MSN
Point72 Asset Management L.P. Takes Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Wasatch Advisors LP Buys Shares of 246,942 Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 3.5%Should You Sell? - MarketBeat
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Short Interest Update - MarketBeat
Eagle Asset Management Inc. Increases Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
(PHAT) Technical Pivots with Risk Controls - Stock Traders Daily
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap DownTime to Sell? - MarketBeat
Jennison Associates LLC Has $106.06 Million Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - MarketBeat
Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's What You Should Know - MSN
Phathom Pharmaceuticals - The Healthcare Technology Report.
(PHAT) Proactive Strategies - Stock Traders Daily
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2024 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals Inc (NASDAQ: PHAT) Up 115.60% This Year: What Is Going To Happen Next - Stocks Register
Phathom Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Business Updates - Defense World
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 8.9%Here's What Happened - MarketBeat
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlig - GuruFocus.com
Phathom Pharmaceuticals Inc (PHAT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Phathom Pharmaceuticals Inc Azioni (PHAT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Phathom Pharmaceuticals Inc Azioni (PHAT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Henderson Molly | CFO and CBO |
Dec 19 '24 |
Sale |
8.00 |
1,291 |
10,328 |
98,156 |
| KARBE FRANK | Director |
Dec 13 '24 |
Buy |
7.93 |
12,500 |
99,084 |
57,000 |
| Parikh Asit | Director |
Dec 13 '24 |
Buy |
8.12 |
10,000 |
81,248 |
75,500 |
| Nabulsi Azmi | Chief Operating Officer |
Jul 15 '24 |
Sale |
11.72 |
10,901 |
127,760 |
240,421 |
| Henderson Molly | CFO and CBO |
Jul 15 '24 |
Sale |
11.72 |
4,325 |
50,689 |
99,447 |
| Curran Terrie | President and Chief Executive |
Jul 15 '24 |
Sale |
11.72 |
33,848 |
396,699 |
377,734 |
| Henderson Molly | CFO and CBO |
Apr 08 '24 |
Sale |
11.10 |
3,435 |
38,128 |
95,263 |
| Curran Terrie | President and Chief Executive |
Mar 22 '24 |
Sale |
9.11 |
16,851 |
153,513 |
410,784 |
| TAKEDA PHARMACEUTICAL CO LTD | 10% Owner |
Jan 24 '24 |
Sale |
8.10 |
3,703,703 |
29,999,994 |
3,755,583 |
| Henderson Molly | CFO and CBO |
Jan 19 '24 |
Sale |
7.75 |
6,307 |
48,900 |
98,698 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):